Sanofi (SAN) Given a €78.00 Price Target by Jefferies Financial Group Analysts

Share on StockTwits

Sanofi (EPA:SAN) has been given a €78.00 ($90.70) price objective by research analysts at Jefferies Financial Group in a report released on Thursday, August 16th. The brokerage currently has a “neutral” rating on the stock. Jefferies Financial Group’s target price would suggest a potential upside of 17.88% from the stock’s previous close.

A number of other research analysts also recently commented on the stock. Goldman Sachs Group set a €74.00 ($86.05) price objective on shares of Sanofi and gave the company a “neutral” rating in a research report on Thursday, June 14th. Citigroup set a €93.00 ($108.14) target price on shares of Sanofi and gave the stock a “buy” rating in a report on Friday, August 10th. JPMorgan Chase & Co. set a €72.00 ($83.72) target price on shares of Sanofi and gave the stock a “neutral” rating in a report on Thursday, May 10th. Deutsche Bank set a €87.00 ($101.16) target price on shares of Sanofi and gave the stock a “buy” rating in a report on Thursday, July 19th. Finally, Credit Suisse Group set a €80.00 ($93.02) target price on shares of Sanofi and gave the stock a “buy” rating in a report on Wednesday, August 1st. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and seven have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of €79.21 ($92.11).

Shares of SAN traded down €0.06 ($0.07) during midday trading on Thursday, reaching €66.17 ($76.94). The stock had a trading volume of 6,890,000 shares, compared to its average volume of 3,050,000. Sanofi has a one year low of €63.09 ($73.36) and a one year high of €92.97 ($108.10).

About Sanofi

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an oral immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Recommended Story: NASDAQ

Analyst Recommendations for Sanofi (EPA:SAN)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.